A literature review covered by UCLA Health reports that the research behind six widely marketed peptide supplements is mostly animal work, and that essentially no studies demonstrated significant clinical benefits for musculoskeletal conditions. The authors analyzed 565 studies looking at effects on musculoskeletal treatment, tissue recovery or performance in animal or human models.

The six compounds are BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu, all sold mostly as self-injectables and promoted online for muscle growth, faster injury healing and slower aging. None are FDA approved, unlike insulin and GLP-1, which UCLA notes are the two best-known approved peptides.

What the 565 studies actually showed

More than two-thirds of the studies were done only in animals, according to Thomas Kremen, MD, a sports medicine specialist at the David Geffen School of Medicine at UCLA and a team physician for the Chargers, Lakers and USA Basketball. He describes promising but variable effects on tendon, muscle, bone and ligament healing, with the caveat that those effects may look very different in rodents than in humans.

A handful of human studies showed modest improvements at best, and only for non-orthopedic indications. The clinical studies that did appear positive were, in Kremen's words, done very poorly, most lacking robust controls or rigorous designs.

Conflicts and safety signals

Co-author and medical student Kushagra Tewari points to conflicting interests, including one of the largest BPC-157 studies, run by a group with a financial interest in the compound. That is the kind of detail that rarely survives into a social media post about the same molecule.

On safety, Kremen cites a documented MK-677 trial halted because of a higher rate of congestive heart failure in one group. He also describes a patient whose cardiac output was too low for outpatient rotator cuff repair and who admitted taking peptides, while saying he cannot establish causality.

What is in the vial

These products are not regulated or vetted by the FDA, and Kremen says some tests have found dangerous substances including arsenic or lead. Material imported from China may arrive labeled not for use in humans before a compounding pharmacy mixes it into something else.

Tewari says compounding pharmacies market these on social media as gray market peptides sold for research purposes only, framing he reads as an attempt to avoid liability.

Bottom line

Kremen's conclusion is blunt: there is little to no evidence these supplements work, and his advice is to wait until the effects are studied rigorously. The interesting part is not that a clinician is skeptical, it is that 565 papers produced so little that speaks directly to the claims being sold.